Metastatic Hormone-Sensitive Prostate Cancer: Benefits and Risks of Current and Emerging Treatment Options

Tuesday, August 11, 2020, 8:00 AM - Tuesday, August 10, 2021, 11:59 PM

AMA PRA Category 1 Credits™ (1.00 hours), AMA PRA Category 1 Credits™ Designated (1.00 hours)

Prostate cancer is the most common cancer in men in the U.S.; in 2018, more than 3 million men were living with the disease. For men in whom prostate cancer is local or regional, 5-year survival approaches 100%. For those with metastatic hormone-sensitive prostate cancer (mHSPC), however, the 5-year survival rate is only 30%. Androgen deprivation therapy (ADT) has long been a treatment mainstay for mHSPC but may be associated with cardiovascular (CV) risks. Recently, the ADT treatment paradigm for mHSPC was modified based on clinical trials demonstrating the effectiveness of docetaxel or abiraterone (with prednisone) in combination with ADT in improving survival in patients with mHSPC. Several other therapies combined with ADT are also available.

In this Virtual Practice, you will meet with two prostate cancer patients—reviewing medical records, assessing symptoms, ordering tests, and evaluating the risks and benefits of different therapeutic options as you develop a treatment plan with the best chance of optimizing outcomes.

Following each case presentation, you will have the opportunity to play Cranium Challenge, a rapid-fire categorization game that puts your clinical knowledge to the test.

There are no fees to participate in the activity. Participants must review all activity content in both modules, including the learning objectives, disclosure statements, and content. To receive CME credit for participation, participants must complete the post-test (achieving a passing grade of 75% or greater) and program evaluation. Certificates can be printed immediately.

Contact Information
For questions regarding CME credit, contact the University of Cincinnati Continuing Medical Education Office. 
For technical questions related to this activity, please email RedMedEd or by calling 610.251.6841.

1. Weigh the benefits and CV risks associated with treatments when providing evidence-based care for patients with mHSPC;
2. Evaluate current and emerging data on treatment advances and appropriately incorporate into practice newer strategies for managing patients with mHSPC.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and RedMedEd. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

The University of Cincinnati designates this enduring material activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Disclosure / Conflict of Interest Policy
In accordance with ACCME requirements, the University of Cincinnati College of Medicine has a conflict of interest policy that requires, all faculty, planning committee members, and other individuals who are in a position to control content, to disclose any relevant relationships with any commercial interest related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence. Disclosure will be made at the time of activity.

Staff Disclosures
The University of Cincinnati, RedMedED, and the peer/content reviewers for this activity have no relevant conflict of interest to report.

Unapproved Product Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The University of Cincinnati; RedMedEd; Astellas and Pfizer, Inc.; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., do not recommend the use of any agent outside the labeled indications.

Disclaimer
The information presented in this activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician regarding diagnosis and treatment of a specific patient’s medical condition. 

The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the University of Cincinnati; RedMedEd; Astellas and Pfizer, Inc.; or Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

This activity is supported by independent educational grants from Astellas and Pfizer, Inc., and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.